Bisphosphonates for Postmenopausal Osteoporosis

This JAMA Women ’s Health summarizes evidence-based use of bisphosphonates for fracture prevention in women with postmenopausal osteoporosis, and reviews potential harms of the drugs and alternative agents (denosumab, raloxifene) for patients with contraindications or intolerance to alendronate, risedronate, or z oledronate.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research